Type 1 Diabetes TrialNet
Study Participants Healthcare Professionals Researchers Locations Publications What is TrialNet? News and Events Get Screened! Home

Publications

Peer Reviewed and Published Articles

The following are published articles authored by Type-1 Diabetes TrialNet investigators and researchers.


TrialNet Study Group Publications

    2004

  1. Palmer JP, Fleming GA, Greenbaum CJ, Herold KC, Jansa LD, Kolb H, Lachin JM, Polonsky KS, Pozzilli P, Skyler JS, Steffes MW. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop. Diabetes 2004; 53:250-264.
  2. Lachin JM. The role of measurement reliability in clinical trials. Clinical Trials 2004; 1:553-566.
  3. 2005

  4. Lachin JM. Maximum Information Designs. Clinical Trials 2005; 2:453-464.
  5. Lachin JM. A review of methods for futility stopping based on conditional power. Statistics in Medicine 2005; 24:2747-2764.
  6. 2006

  7. Lachin JM. Operating characteristics of sample size re-estimation with futility stopping based on conditional power. Statistics in Medicine 2006; 25:3348-3365.
  8. 2007

  9. Lachin JM, Younes N. A composite design for transition from a preliminary to a full-scale study. Statistics in Medicine 2007; 26:5014–5032.
  10. 2008

  11. Skyler JS, Greenbaum CJ, Lachin JM, Leschek E, Rafkin-Mervis L, Savage P, Spain L, and the Type 1 Diabetes TrialNet Study Group. Type 1 Diabetes TrialNet – An International Collaborative Clinical Trials Network. Annals of the New York Academy of Sciences 2008; In Press.
  12. Skyler JS and the Type 1 Diabetes TrialNet Study Group. Update on Worldwide Efforts to Prevent Type 1 Diabetes. Annals of the New York Academy of Sciences 2008; In Press.
  13. Greenbaum CJ, Mandrup-Poulsen T, Friedenberg-McGee P, Battelino T, Haastert B, Ludvigsson J, Pozzilli P, Lachin JM, Kolb H, and The Type 1 Diabetes TrialNet Research Group and The European C-peptide Trial Study Group. Mixed-Meal Tolerance Test Versus Glucagon Stimulation Test for the Assessment of β-Cell Function in Therapeutic Trials in Type 1 Diabetes. Diabetes Care 2008; 31: 1966-1971.
  14. 2009

  15. Mahon J, Sosenko JM, Rafkin-Mervis LE, Krause-Steinrauf H, Lachin JM, Thompson C, Bingley PJ, Bonifacio E, Palmer JP, Eisenbarth GS, Wolfsdorf J, Skyler JS, for the TrialNet Natural History Committee and Type 1 Diabetes TrialNet Study Group. The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results. Pediatric Diabetes 2008: [Epub ahead of print] doi: 10.1111/j.1399-5448.2008.00464.
  16. Chase HP, Lescheck E, Rafkin-Mervis L, Krause-Steinrauf H, Chritton S, Asare S, Adams S, Skyler JS, Clare-Salzier M, and the Type 1 Diabetes Trialnet NIP Study Group. Nutritional Intervention to Prevent (NIP) Type 1 Diabetes: A Pilot Trial. iCAN: Infant, Child and Adolescent Nutrition 2009: 99-107.
  17. 12. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, Goland R, Gottlieb PA, Marks JB, McGee PF, Moran AM, Raskin P, Rodriguez H, Schatz D, Wherrett D, Wilson DM, Lachin JM, Skyler JS, and The Type 1 Diabetes TrialNet Anti-CD20 Study Group. Rituximab, B-lymphocyte Depletion and Preservation of Beta-cell Function. New England Journal of Medicine 2009; 361:2143-2152.
  18. 13. Herold KC, Brooks-Worrell B, Palmer JP, Dosch HM, Peakman M, Gottlieb PA, Reijonen H, Arif S, Spain LM, Thompson C, Lachin JM, and The Type 1 Diabetes TrialNet Research Group. Validity and Reproducibility of Measurement of Islet Autoreactivity by T-cell Assays in Subjects with Early Type 1 Diabetes. Diabetes 2009; 58:2588-2595.
  19. 2010

  20. Bingley PJ, Matthews CL. Type 1 Diabetes TrialNet: Working Together to Prevent, Delay or Slow the Progression of Type 1 Diabetes. Pract Diab Int 2010;27:98-99i.
  21. Gottlieb PA, Quinlan S, Krause-Steinrauf H, Greenbaum CJ, Wilson DM, Rodriguez H, Schatz DA, Moran AM, Lachin JM, Skyler JS, and the Type 1 Diabetes TrialNet MMF/DZB Study Group. Failure to Preserve B-Cell Function With Mycophenolate Mofetil and Daclizumab Combined Therapy in Patients With New-Onset Type 1 Diabetes. Diabetes Care 2010; 33: 826-832. PMID 20067954, PMC2845036.
  22. 2011

  23. Orban T, Bundy B, Becker DJ, DiMeglio L, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Marks JB, Monzavi R, Moran AM, Raskin P, Rodriguez H, Russell WE, Schatz D, Wherrett D, Wilson DM, Krischer JP, Skyler JS and the Type 1 Diabetes TrialNet Abatacept Study Group. Co-Stimulation Modulation with Abatacept in Patients with Recent-Onset Type 1 Diabetes: A Randomized Double-Masked Controlled Trial. Lancet 2011;378:412-419. PMID 21719096.
  24. Vehik K, Beam CA, Mahon JL, Schatz DA, Haller MJ, Sosenko JM, Skyler JS, Krischer JP for the TrialNet Natural History Study Group. Development of Autoantibodies in the TrialNet Natural History Study (NHS). Diabetes Care 2011;34(9):1897-1901. PMID 21750277, PMC3161292.
  25. Wherrett D, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Herold KC, Marks JB, Monzavi R, Moran A, Orban T, Raskin P, Rodrigues H, Schatz D, Wilson DM, Krischer JP, Skyler JS, the TrialNet GAD Study Group. Antigen-Based Therapy with Glutamic Acid Decarboxylase (GAD) Vaccine in Patients with Recent-Onset Type 1 Diabetes: A Randomised Double-Masked Controlled Trial. Lancet 2011;378:319-327. PMID 21714999.
  26. Herold K, Pescovitz M, McGee P, Krause-Steinrauf H, Spain L, Bourcier K, Asare A, Liu Z, Lachin J, Dosch HM, for the Type 1 Diabetes TrialNet Study Group. Increased T Cellular Proliferative Responses to Islet Antigens Identify Clinical Responders to Anti-CD20 Monoclonal Antibody (Rituximab) Therapy in Type 1 Diabetes. J Immunology2011;187:1998-2005. PMID 21775681, PMC3150302, NIHMS303803.
  27. Yu L, Herold K, Lachin J, Bundy B, Pugliese A, Krischer J, Eisenbarth G, Pescovitz M, Type 1 Diabetes TrialNet Anti-CD20 Study Group. Rituximab Selectively Suppresses Specific Islet Antibodies. Diabetes 2011;60:2560-2565. PMIC21831969, PMC3178300.
  28. Mahon JL, Beam CA, Marcovina SM, Boulware DC, Palmer JP, Winter WE, Skyler JS, Krischer JP and the Type 1 Diabetes TrialNet Study Group. Comparison of Two Insulin Assays for First-Phase Insulin Release in Type 1 Diabetes Prediction and Prevention Studies. Clin Chim Acta 2011;412:2128-2131. PMID 21843518, PMC3150302, NIHMS303803.
  29. Pescovitz M, Torgerson TR, Ochs HD, Ocheltree E, McGee P, Krause-Steinrauf H, Lachin JM, Canniff J, Greenbaum C, Herold KC, Skyler JS, Weinberg A, the Type 1 Diabetes TrialNet Study Group. Effect of Rituximab on Human In Vivo Antibody Immune Responses. J Allergy Clin Immunol 2011;128:1295-1302.e5, PMID 21908031, PubMed in process.
  30. Lachin J, Friedenberg-McGee P, Greenbaum CJ, Spain L, Palmer J, Pescovitz MD, Gottlieb P, Skyler J, for the Type 1 Diabetes TrialNet Study Group. Sample Size Requirements for Studies of Treatment Effects on Beta-Cell Function in Newly Diagnosed Diabetes. PLOS One 2011;6(11): e26471. PMID: 22102862, PMC3213096.
  31. 2012

  32. Yu L, Boulware DC, Beam CA, John C. Hutton JC, Wenzlau JM, Greenbaum CJ, Bingley PJ, Krischer JP, Sosenko JM, Skyler JS, Eisenbarth GS, Mahon JL for the Type 1 Diabetes TrialNet Study Group. Zinc Transporter-8 Autoantibodies Improve Prediction of Type 1 Diabetes in Relatives Positive for the Standard Biochemical Autoantibodies. Diabetes Care 2012;35:1213-1218. PMID 22446173, PMC3357246
  33. Greenbaum CJ, Beam CA, Boulware D, Gitelman SE, Gottlieb PA, Herold KC, Lachin JM, McGee P, Palmer JP, Pescovitz MD, Krause-Steinrauf H, Skyler JS, Sosenko JM, Type 1 Diabetes TrialNet Study Group. Fall in C-peptide Over First Two Years from Diagnosis: Evidence of At Least Two Distinct Phases from Composite TrialNet Data. Diabetes 2012;61:2066-2073. PMID 22688329, PMC3402330
  34. Vehik K, Cuthbertson D, Boulware D, Beam CA, Rodriguez H, Legault L, Hyytinen M, Rewers M, Schatz DA, Krischer JP,  and the TEDDY, TRIGR, Diabetes Prevention Trial-Type 1 and Type 1 Diabetes TrialNet Natural History Study Groups. Performance of HbA1c as an Early Diagnostic Indicator of Type 1 Diabetes in Children and Youth. Diabetes Care 2012;35:1821-1825. PMID 22699293, PMC3425003
  35. Long SA, Rieck M, Sanda S, Bollyky JB, Samuels PL, Goland R, Ahmann A, Rabinovitch A, Aggarwal S, Phippard D, Turka LA, Ehlers MR, Bianchine PJ, Boyle KD, Adah SA, Bluestone JA, Buckner JH, Greenbaum CJ; for the Diabetes TrialNet and the Immune Tolerance Network. Rapamycin/IL-2 Combination Therapy in Patients with Type 1 Diabetes Augments Tregs yet Transiently Impairs β-Cell Function. Diabetes 2012; 61:2340-2348. PMID 22721971, PMC3425404
  36. 2013

  37. Sajjadi SJ, Qian X, Zeng B. Network-Based Methods to Identify Highly Discriminating Subsets of Biomarkers. 2012 IEEE International Workshop on Genomic Signal Processing and Statistics (GENSIPS), "Data Mining and Modeling Methods in Next-Generation Sequencing and Cancer Systems Biology". Washington DC, December 2-4, 2012, IEEE Xplore, in press.

  38. Moran A, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Greenbaum CJ, Herold KC, Marks JB, Sanda S, Raskin P, Schatz D, Wherrett DK, Wilson DM, Krischer JP, Skyler JS, Pickersgill L, de Koning E, Ziegler A-G, Boehm B, Badenhoop K, Schloot N, Bak JF, Pozzilli P, Mauricio D, Donath MY, Castano L, Wagner A, Lervang HH, Perrild H, Mandrup-Poulsen T. Interleukin-1 Antagonism in Type 1 Diabetes of Recent Onset: Two Multicenter, Randomized Double-Masked, Placebo-Controlled Trials. April 5, 2013 Lancet Epub ahead of print.

  39. Kroll JL, Beam C, Li S, Viscidi R, Pescovitz M, Weinberg A, the Type 1 Diabetes TrialNet Anti CD-20 Study Group. Reactivation of Latent Viruses in Individuals Receiving Rituximab for New Onset Type 1 Diabetes. J Clin Virol 2013;57:115-119. PMID 23422292. PMC3526252.

  40. Diabetes Research in Children Network (DirecNet) and Type 1 Diabetes TrialNet Study Groups. The Effects of Inpatient Hybrid Closed-Loop Therapy Initiated within 1 Week of Type 1 Diabetes Diagnosis. Diabetes Technol Ther 2013;15:401-408. PMID 23570538.

  41. Elding Larssona H, Jönsson I, Åke Lernmark Å, Ivarsson S, Radtke JR, Hampe CS and the Diabetes Prediction in Skåne (DiPiS) and Type 1 Diabetes TrialNet studies. Decline in Titers of Anti-Idiotypic Antibodies Specific to Autoantibodies to GAD65 (GAD65Ab) Precedes Development of GAD65Ab and Type 1 Diabetes. Plos One, accepted 4/23/13.

  42. Sosenko JM, Skyler JS, Palmer JP, Krischer JP, Yu L, Mahon J, Beam CA, Boulware DC, Rafkin L, Schatz D, Eisenbarth G, the Type 1 Diabetes TrialNet and the Diabetes Prevention Trial-Type 1 Study Groups. The Prediction of Type 1 Diabetes by Multiple Autoantibody Levels and Their Incorporation into an Autoantibody Risk Score in Relatives of Type 1 Diabetes Patients. Diabetes Care accepted 5/10/13.


back to top of page

DPT-1 Study Group Publications

    1995

  1. DPT-1 Study Group. The Diabetes Prevention Trial-Type 1 Diabetes (DPT-1). Implementation of Screening and Staging of Relatives. Transplantation Proceedings 1995; 27: 3377.
  2. 2000

  3. Greenbaum CJ, Schatz DA, Cuthbertson D, Zeidler A, Eisenbarth GS, Krischer JP, The Diabetes Prevention Trial–Type 1 Study Group. Islet Cell Antibody-Positive Relatives With Human Leukocyte Antigen DQA1*0102, DQB1*0602: Identification by the Diabetes Prevention Trial-Type 1. Journal of Clinical Endocrinology & Metabolism 2000; 85:1255-1260
  4. 2001

  5. Greenbaum CJ, Cuthbertson D, Krischer JP, and the Diabetes Prevention Trial of Type 1 Diabetes Study Group. Type 1 Diabetes Manifested Solely by 2-h Oral Glucose Tolerance Test Criteria. Diabetes 2001; 50:470-476
  6. Chase HP, Cuthbertson DD, Dolan LM, Kaufman F, Krischer JP, Schatz DA, White NH, Wilson DM, Wolfsdorf J, The Diabetes Prevention Trial–Type 1 Study Group. First-phase Insulin Release During The Intravenous Glucose Tolerance Test As A Risk Factor For Type 1 Diabetes. Journal of Pediatrics 2001; 138:244-249
  7. Yu L, Cuthbertson DD, Maclaren N, Jackson R, Palmer JP, Orban T, Eisenbarth GS, Krischer JP, DPT-1 Participating Investigators. Expression of GAD65 and Islet Cell Antibody (ICA512) Autoantibodies Among Cytoplasmic ICA+ Relatives Is Associated With Eligibility for the Diabetes Prevention Trial-Type 1. Diabetes 2001; 50: 1735-1740.
  8. 2002

  9. Diabetes Prevention Trial - Type 1 Diabetes Study Group. Effects of Insulin in Relatives of Patients with Type 1 Diabetes Mellitus. New England Journal of Medicine 2002; 346:1685-1691.
  10. Yu L, Cuthbertson DD, Eisenbarth GS, Krischer JP, DPT-1 Participating Investigators. Diabetes Prevention Trial 1: Prevalence of GAD and ICA512 (IA-2) Autoantibodies by Relationship to Proband. Annals of the New York Academy of Sciences 2002; 958:254-258.
  11. 2003

  12. Krischer JP, Cuthbertson DD, Yu L, Orban T, Maclaren N, Jackson R, Winter WE, Schatz DA, Palmer JP, Eisenbarth GS, and The Diabetes Prevention Trial–Type 1 Study Group. Screening Strategies for the Identification of Multiple Antibody Positive Relatives of Individuals with Type 1 Diabetes. Journal of Clinical Endocrinology & Metabolism 2003; 88:103-108.
  13. 2004

  14. Redondo MJ, Fain PR, Krischer JP, Yu L, Cuthbertson D, Winter WE, Eisenbarth GS; on behalf of the DPT-1 Study Group. Expression of beta-cell autoimmunity does not differ between potential dizygotic twins and siblings of patients with type 1 diabetes. Journal of Autoimmunity 2004; 23:275-279.
  15. Krischer JP, Cuthbertson DD, Greenbaum C; Diabetes Prevention Trial-Type 1 Study Group. Male sex increases the risk of autoimmunity but not type 1 diabetes. Diabetes Care 2004; 27:1985-1990.
  16. 2005

  17. Greenbaum CJ, Eisenbarth G, Atkinson M, Yu L, Babu S, Schatz D, Zeidler A, Orban T, Wasserfall C, Cuthbertson D, Krischer J, DPT-1 Study Group. High Frequency of Abnormal Glucose Tolerance in DQA1*0102/DQB1*0602 Relatives Identified as Part of the Diabetes Prevention Trial – Type 1 Diabetes. Diabetologia 2005; 48:68-74.
  18. Diabetes Prevention Trial - Type 1 Diabetes Study Group. Effects of Oral Insulin in Relatives of Patients with Type 1 Diabetes Mellitus. Diabetes Care 2005; 28:1068-1076.
  19. Rhodes, ET, Wolfsdorf, JI, Cuthbertson, DD, Feldman, HA, Ludwig, DS; Diabetes Prevention Trial-Type 1 Study Group. Effect of low-dose insulin treatment on body weight and physical development in children and adolescents at risk for type 1 diabetes. Diabetes Care 2005; 28:1948-1953.
  20. 2006

  21. Sosenko JM, Palmer JP, Greenbaum CJ, Mahon J, Cowie C, Krischer JP, Chase HP, White NH, Buckingham B, Herold KC, Cuthbertson D, Skyler JS, and the Diabetes Prevention Trial-1 Study Group. Patterns of Metabolic Progression to Type 1 Diabetes in the Diabetes Prevention Trial–Type 1. Diabetes Care 2006;29:643-649.
  22. Tsai EB, Sherry NA, Palmer JP, Herold KC, and the DPT-1 Study Group. The Rise and Fall of Insulin Secretion in Type 1 Diabetes Mellitus. Diabetologia 2006;49:261-270.
  23. Redondo MJ, Babu S, Zeidler A, Orban T, Yu L, Greenbaum C, Palmer JP, Cuthbertson D, Eisenbarth GS, Krischer JP, Schatz D, and the DPT-1 Study Group. Specific HLA DQ Influence on Expression of Anti-Islet Autoantibodies and Progression to Type 1 Diabetes. J Clin Endocrinol Metab 2006;91:1705-1713.
  24. 2007

  25. Redondo MJ, Babu S, Zeidler A, Orban T, Yu L, Greenbaum C, Palmer JP, Cuthbertson D, Eisenbarth GS, Krischer JP, Schatz D, and the DPT-1 Study Group. Specific HLA DQ Influence on Expression of Anti-Islet Autoantibodies and Progression to Type 1 Diabetes. Journal of Clinical Endocrinology & Metabolism 2006; 91: 1705-1713.
  26. Sosenko JM, Palmer JP, Greenbaum CJ, Mahon J, Cowie C, Krischer JP, Chase HP, White NH, Buckingham B, Herold KC, Cuthbertson D, Skyler JS, and the Diabetes Prevention Trial-1 Study Group. Increasing the accuracy of oral glucose tolerance testing and extending its application to individuals with normal glucose tolerance for the prediction of type 1 diabetes: the Diabetes Prevention Trial- Type 1. Diabetes Care 2007; 30:38-42.
  27. Barker JM, McFann KK, Orban T, on behalf of the DPT-1 Study Group. Effect of oral insulin on insulin autoantibody levels in the Diabetes Prevention Trial Type 1 oral insulin study. Diabetologia 2007; 50:1603-1606.
  28. Xu P, Cuthbertson D, Greenbaum C, Palmer JP, Krischer JP, and Diabetes Prevention Trial-Type 1 Study Group. The Role of Insulin Resistance in Predicting the Progression to Type 1 Diabetes. Diabetes Care 2007; 30:2314–2320.
  29. Johnson, SB, Baughcum, AE, Hood K, Rafkin-Mervis, LE, Schatz, DA, for the DPT-1 Study Group. Participant and Parent Experiences in the Parenteral Insulin Arm of the Diabetes Prevention Trial for Type 1 Diabetes. Diabetes Care, 2007; 30:2193–2198.
  30. 2008

  31. Sosenko JM, Krischer JP, Palmer JP, Mahon J, Cowie C, Greenbaum CJ, Cuthbertson D, Lachin JM, Skyler JS, and the Diabetes Prevention Trial-1 Study Group. A Risk Score for Type 1 Diabetes Derived from Autoantibody Positive Participants in The Diabetes Prevention Trial-Type 1. Diabetes Care 2008; 31: 528-533.
  32. Sosenko JM, Palmer JP, Rafkin-Mervis L, Krischer J, Cuthbertson D, Matheson D, Skyler JS, and the DPT-1 Study Group. Glucose and C-peptide Changes in the Peri-Onset Period of Type 1 Diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2008; 31: Jul 23. [Epub ahead of print].
  33. Butty V, Campbell C, Mathis D, Benoist C, and the Diabetes Prevention Trial-Type 1 Study Group. Impact of diabetes susceptibility loci on progression from pre-diabetes to diabetes in at-risk individuals of the DPT1 trial. Diabetes 2008; 57: 2348-2359.
  34. Sherr J, Sosenko J, Skyler JS, Herold K. Prevention of Type 1 diabetes. The time has come. Nature Clinical Practice Endocrinology & Metabolism 2008; 4:334-343.
  35. 2009

  36. Johnson SB, Baughcum AE, Rafkin-Mervis LE, Schatz DA, for the DPT-1 Study Group. Participant and parent experiences in the oral insulin study of the Diabetes Prevention Trial for Type 1 Diabetes. Pediatric Diabetes 2008; [Epub ahead of print] doi: 10.1111/j.1399-5448.2008.00463.x.
  37. Sosenko JM, Palmer JP, Rafkin-Mervis L, Krischer J, Cuthbertson D, Skyler JS, and the DPT-1 Study Group. Incident Dysglycemia and the Progression to Type 1 Diabetes among Participants in the Diabetes Prevention Trial-Type 1. Submitted for Publication.
  38. Triolo TM, Chase HP, Barker JM, for the DPT-1 Study Group. Subjects diagnosed with diabetes through the Diabetes Prevention Trial Type 1 are often asymptomatic and have normal hemoglobin A1c levels at onset. Submitted for Publication.
  39. Orban T, Sosenko JM, Cuthbertson D, Krischer JP, Skyler JS, Jackson R, Yu L, Palmer JP, Schatz DA, Eisenbarth GS, and the DPT-1 Study Group. Pancreatic Islet Cell Autoantibodies as Predictors of Type 1 Diabetes in the Diabetes Prevention Trial-Type 1 (DPT-1). Diabetes Care 2009; 32:2269-2274.
  40. 2010

  41. Sosenko JM, Palmer JP, Rafkin LE, Krischer JP, Cuthbertson D, Greenbaum CJ, Eisenbarth GS, Skyler JS, and the DPT-1 Study Group. Trends of Earlier and Later Responses of C-Peptide to Oral Glucose Challenges with Progression to Type 1 Diabetes in Diabetes Prevention Trial-Type 1 Participants. Diabetes Care 2010;33:620-625. PMID20032282, PMC2827520
  42. Ferrannini E, Mari A, Nofrate V, Sosenko JM, Skyler JS, for the DPT-1 Study Group. Progression to Diabetes in Relatives of Patients with Type 1 Diabetes: Mechanisms andMode of Onset. Diabetes 2010;59:679-685. PMID 20028949, PMC282866
  43. Sosenko J, Skyler J, Krischer J, Greenbaum C, Mahon J, Rafkin-Mervis L, Cuthbertson D, Cowie C, Herold K, Eisenbarth G, Palmer J, the Diabetes Prevention Trial-1 Study Group. Glucose Excursions between States of Glycemia with Progression to Type 1 Diabetes in the Diabetes Prevention Trial Type 1 (DPT-1). Diabetes 2010;59:2386-2389. PMID 20682683
  44. Xu P, Wu Y, Zhu Y, Dagne G, Johnson G, Cuthbertson D, Krischer J, Skyler J, Sosenko J, and the Diabetes Prevention Trial-1 Study Group. Prognostic Performance of Metabolic Indexes in Predicting Onset of Type 1 Diabetes. Diabetes Care 2010;33:2508-2513. PMID 20807869, PMC2992179
  45. 2011

  46. Sosenko JM, Mahon J, Rafkin-Mervis L, Lachin JM, Krause-Steinrauf H, Krischer JP, Cuthbertson D, Palmer JP, Thompson C, Greenbaum CJ, Skyler JS, the Diabetes Prevention Trial-Type 1 Diabetes (DPT-1) and Type 1 Diabetes TrialNet Study Groups. A Comparison of the Baseline Metabolic Profiles Between Diabetes Prevention Trial-Type 1 and TrialNet Natural History Study Participants. Pediatric Diabetes 2011;12:85-90. PMID 20522170, NIHMS213978, PMC2955175
  47. Greenbaum CJ, McCulloch-Olson M, Chiu HK, Palmer JP, Brooks-Worrell B. ParenteralInsulin Suppresses T Cell Proliferation to Islet Antigens. Pediatric Diabetes 2011;12;150-155. PMID 20522167, NIHMS213975, PMC2957543
  48. Vehik K, Haller MJ, Beam CA, Schatz DA, Wherrett DK, Sosenko JM, Krischer J, theDPT-1 Study Group. Islet Autoantibody Seroconversion in the DPT-1 Study: Justification for Repeat Screening Throughout Childhood. Diabetes Care 2011;34:358-362. PMID21270193, PMC3024349
  49. Greenbaum CJ, Buckingham B, Chase HP, Krischer J. Metabolic Tests to Determine Risk for Type 1 Diabetes in Clinical Trials. Diabetes Metab Res Rev 2011;27:584-589. PMID21488143, NIHMS287843, PMC3162108
  50. Vehik K, Cuthbertson D, Ruhling H, Schatz DA, Peakman M, Krischer JP, on behalf of the DPT-1 & TrialNet Study Groups. Long Term Outcome of Individuals Treated with Oral Insulin: Diabetes Prevention Trial-Type 1 (DPT-1) Oral Insulin Trial. Diabetes Care2011;34:1585-1590. PMID: 21610124, PMC3120180
  51. Sosenko JM, Skyler JS, Mahon J, Krischer JP, Beam CA, Boulware DC, Greenbaum CJ, Rafkin LE, Cowie C, Cuthbertson D, Palmer JP, the TrialNet and Diabetes Prevention Trial– Type 1 Study Groups. The Validation of the Diabetes Prevention Trial-Type 1 RiskScore and the Detection of Pre-Diabetes in the TrialNet Natural History Study. DiabetesCare 2011;34:1785-1787. PMID: 21680724, PMC3142063.
  52. Sosenko JM, Skyler JS, Palmer JP, Krischer JP, Cuthbertson D, Yu L, Schatz DA, Orban T, Eisenbarth G, Diabetes Prevention Trial-Type 1 and Type 1 Diabetes TrialNet Study Groups. A Longitudinal Study of GAD65 and ICA512 Autoantibodies during the Progression to Type 1 Diabetes in Diabetes Prevention Trial-Type 1 (DPT-1) Participants. (Brief Report) Diabetes Care 2011;34:2435-2437. PMID 21911777, PMC3198298.
  53. Mahon JL, Beam CA, Marcovina SM, Boulware DC, Palmer JP, Winter WE, Skyler JS, Krischer JP and the Type 1 Diabetes TrialNet Study Group. Comparison of Two Insulin Assays for First-Phase Insulin Release in Type 1 Diabetes Prediction and Prevention Studies. Clin Chim Acta 2011;412:2128-2131. PMID 21843518, PMC3150302, NIHMS303803
  54. Pescovitz M, Torgerson TR, Ochs HD, Ocheltree E, McGee P, Krause-Steinrauf H, Lachin JM, Canniff J, Greenbaum C, Herold KC, Skyler JS, Weinberg A, the Type 1 Diabetes TrialNet Study Group. Effect of Rituximab on Human In Vivo Antibody Immune Responses. J Allergy Clin Immunol 2011;128:1295-1302.e5, PMID 21908031
  55. Lachin J, Friedenberg-McGee P, Greenbaum CJ, Spain L, Palmer J, Pescovitz MD, Gottlieb P, Skyler J, for the Type 1 Diabetes TrialNet Study Group. Sample Size Requirements for Studies of Treatment Effects on Beta-Cell Function in Newly Diagnosed Diabetes. PLOS One 2011;6(11): e26471. PMID 22102862, PMC3213096
  56. 2012

  57. Sosenko JM, Skyler JS, Herold KC, Palmer JP. The Metabolic Progression to Type 1 Diabetes as Indicated by Serial Oral Glucose Tolerance Testing in the Diabetes Prevention Trial-Type 1. Diabetes 2012;61:1331-1337. PMID 22618768, PMC3357303

  58. Sosenko JM, Skyler JS, Mahon J, Krischer JP, Beam CA, Boulware DC, Greenbaum CJ, Rafkin LE, Cowie C, Cuthbertson D, Palmer JP, The TrialNet and Diabetes Prevention Trial-Type 1 Study Groups. The Application of the Diabetes Prevention Trial Risk Score (DPTRS) for Identifying a Pre-Clinical State of Type 1 Diabetes. Diabetes Care 2012;35:1552-1555. PMID 22547092, PMC3379597

  59. Xu P, Beam CA, Cuthbertson D, Sosenko JM, Skyler JS, Krischer JP and the DPT-1 Study Group..  Prognostic Accuracy of Immunologic and Metabolic Markers for Type 1 Diabetes in a High Risk Population - Receiver Operating Characteristic Analysis. Diabetes Care 2012;35:1975-1980. PMID 22787174, PMC3447832
  60. 2013

  61. Loechelt BJ, Boulware D, Green M, Baden LR, Gottlieb P, Krause-Steinrauf H, Weinberg A for the Type 1 Diabetes TrialNet Daclizumab/Mycophenolic Acid Study Group. Epstein Barr & Other Herpesvirus Infections in Patients with Early Onset Type 1 Diabetics Treated with Daclizumab & Mycophenolic Mofetil. Clinical Infectious Diseases 2013; 56:248-254. PMID 23042974, PMC3526252

  62. Adl AA, Qian X, Xu P, Vehik K, Krischer JP. Feature Ranking Based on Synergy Networks to Identify Prognostic Markers in DPT-1. 2012 IEEE International Workshop on Genomic Signal Processing and Statistics (GENSIPS), "Data Mining and Modeling Methods in Next-Generation Sequencing and Cancer Systems Biology". Washington DC, December 2-4, 2012, IEEE Xplore, in press.

back to top of page

Abstracts Published

    1994

  1. DPT-1 Study Group. The Diabetes Prevention Trial of Type I Diabetes (DPT-1). Diabetes 1994; 43(Suppl 1):159A
  2. 1995

  3. DPT-1 Study Group. The Diabetes Prevention Trial-Type 1 Diabetes (DPT-1): Implementation of Screening and Staging of Relatives. Diabetes 1995; 44(Suppl 1):129A.
  4. Schatz D for the DPT-1 Study Group. The Diabetes Prevention Trial-Type 1 Diabetes (DPT-1): Design and Implementation of the Oral Antigen (Insulin) Protocol. Diabetes 1995; 44(Suppl 1):230A.
  5. DPT-1 Study Group. The Diabetes Prevention Trial-Type 1 Diabetes (DPT-1): Progress Report. Autoimmunity 1995; 21:66.
  6. 1996

  7. Eisenbarth GS, Krischer J, Greenbaum C, Schatz D, Skyler J, for the DPT-1 Study Group. Differential Expression of Autoantibodies by DQA1*0102,DQB1*0602+ Relatives of The Diabetes Prevention Trial-1 (DPT-1). Autoimmunity 1996; 24(Suppl 1):52.
  8. 1997

  9. DPT-1 Study Group. The Diabetes Prevention Trial-Type 1 Diabetes (DPT-1): Enrollment Report. Diabetes 1997; 46(Suppl 1):163A.
  10. DPT-1 Study Group. Demographics of Relatives Screened and ICA Positive in The Diabetes Prevention Trial-Type 1 Diabetes (DPT-1). Diabetes 1997; 46(Suppl 1):142A.
  11. DPT-1 Study Group. The Diabetes Prevention Trial-Type 1 Diabetes (DPT-1): Progress Report. Diabetologia 1997; 40(Suppl 1):A66.
  12. DPT-1 Study Group. The Diabetes Prevention Trial-Type 1 Diabetes (DPT-1): Demographics of Relatives Screened and ICA Positive. Diabetologia 1997; 40(Suppl 1):A78.
  13. Eisenbarth GS, Krischer J, Greenbaum C, Schatz D, Skyler J, for the DPT-1 Study Group. Role of DQA1*0102/DQB1*0602 In Risk Characterization: The Diabetes Prevention Trial-Type 1 Diabetes (DPT-1). Diabetologia 1997; 40(Suppl 1):A48.
  14. Eastman RC, Cowie CC, Harmon J, and the DPT-1 Study Group. Potential Cost-Effectiveness of Primary Prevention of Insulin-Dependent Diabetes Mellitus. Diabetologia 1997; 40(Suppl 1):A39. 
  15. 1998

  16. Cowie C, Cuthbertson D, Krischer J, Wilson D, Maclaren N, and the DPT-1 Study Group. Demographic Characteristics of Islet Cell Antibody Positivity (ICA+) in The Diabetes Prevention Trial for Type 1 Diabetes (DPT-1). Diabetes 1998; 47(Suppl 1):A146.
  17. Greenbaum CJ, Zeidler A, Schatz D, Eisenbarth G, Cuthbertson D, Krischer J, and the DPT-1 Study Group Characteristics of HLA DQA1*0102 DQB1*0602 Relatives Identified in The Diabetes Prevention Trial - Type 1 Diabetes (DPT-1). Diabetes 1998; 47(Suppl 1):A236.
  18. Greenbaum CJ, Cuthbertson D, Krischer J, and the DPT-1 Study Group. Undiagnosed Hyperglycemia in Relatives of Type 1 Diabetes Patients. Diabetes 1998; 47(Suppl 1):A236.
  19. 1999

  20. Greenbaum CJ, Cuthbertson D, Krischer J, and the DPT-1 Study Group. Silent Type 1 Diabetes. Diabetes 1999; 48:(Suppl 1):A81.
  21. Palmer J, Wei, Greenbaum C, Krischer J, Cuthbertson D, and the DPT-1 Study Group. The DPT-1 Intravenous Insulin Suppresses Endogenous Insulin Secretion But Causes Post-Prandial Glucose Intolerance. Diabetes 1999; 48:(Suppl 1):A295.
  22. Yu L, Cuthbertson DD, Maclaren N, Jackson R, Eisenbarth GS, Krischer JP, and the DPT-1 Study Group. Expression of GAD65 or ICA 512 (IA-2) Autoantibodies Amongst Cytoplasmic ICA Positive Relatives is Associated with Eligibility for DPT-1. Diabetes 1999; 48:(Suppl 1):A214.
  23. Chase P, Cuthbertson D, Dolan L, Kaufman F, Krischer J, Schatz D, White N, Wilson D, Wolfsdorf J, and the DPT-1 Study Group. First Phase Insulin Release (FPIR) During the Initial Intravenous Glucose Tolerance Test (IV-GTT) in the Diabetes Prevention Trial (DPT-1). Diabetes 1999; 48:(Suppl 1):A238-239.
  24. 2001

  25. Kaufman F, Cuthbertson D, Krischer J and the DPT-1 Study Group. HbA1c Corrlatated with Fasting and Postprandial Glucose Levels in Subjects in the Diabetes Prevention Trial-type 1 (DPT-1). Diabetes 2001; 50(Suppl 1) A96
  26. Kaufman F, Rafkin-Mervis L, Ricker A, Wherrett D and the DPT-1 Study Group. Recruitment of Subjects into the Diabetes Prevention Trial-Type 1 (DPT-1):Strategies and Progress Report from 1994-2000. Diabetes 2001; 50(Suppl 1) A96
  27. 2003

  28. Navidi G, Kolva R, Younes N, Zhou A. Use of Barcodes for Specimen Tracking to Maintain Patient Confidentiality and Quality Control Measures. Controlled Clinical Trials 2003; 24(3S): 218S.
  29. Zhou A, Younes N, Pierre D, Krause-Steinrauf H. TrialNet Document and Sample Tracking System. Controlled Clinical Trials 2003; 24(3S): 219S.
  30. 2004

  31. Paula Friedenberg P, Lachin J, for the TrialNet Study Group. Sample Size Evaluaton for Studies of Beta-Cell Function Using the Log(C-Peptide + 1) Transformation. Clinical Trials2004; 2: 256.
  32. Redondo MJ, Babu S, Zeidler A, Orban T, Yu L, Cuthbertson D, Eisenbarth GS, Krischer J, Schatz D. Diabetes Prevention Trial (DPT)-1: Influence of Protective HLA-DQ Alleles and Genotypes on Expression of Autoantibodies (Aab) and Progression to Type 1 Diabetes (T1DM). Diabetes 2004; 53(Suppl 1):A29(125-OR)
  33. Sosenko JM, Greenbaum CJ, Palmer JP, Cowie CC, White NH, Cuthbertson DD, Krischer JP, Skyler JS, The DPT-1 Study Group. Fasting Insulin Secretion Is Maintained More Than Stimulated Insulin Secretion with Progression to Type 1 Diabetes (T1D) in the Diabetes Prevention Trial-Type 1 (DPT-1). Diabetes 2004; 53(Suppl 1):A425 (1783-P)
  34. Rhodes E, Wolfsdorf J, Feldman H, Ludwig D, DPT-1 Study Group. Effect of Low-Dose Insulin Treatment on Body Weight and Adiposity in Children at Risk of Type 1 Diabetes Mellitus. Diabetes 2004; 53(Suppl 1):A415 (1743-P)
  35. 2005

  36. Sosenko JM, Palmer JP, Greenbaum CJ, Cowie CC, Mahon J, Chase HP, White NH, Cuthbertson DD, Krischer JP, Skyler JS, The DPT-1 Study Group. The 2-hr-Glucose and the AUC Glucose-AUC C-Peptide Ratio as Predictors of T1D in Diabetes Prevention Trial-Type 1 (DPT-1) Participants. Diabetes 2005; 54(Supplement 1): A456 (1897-P).
  37. Quinlan S, Krause-Steinrauf H, Gottlieb P, for the TrialNet Study Group. Recruitment and Informed Consent for a Clinical Trial in Subjects with New-Onset Diabetes Mellitus. Clinical Trials 2005; 2: S57.
  38. 2006

  39. Lachin JM, Friedenberg P, Greenbaum C, Colman P, on behalf of Type 1 Diabetes TrialNet. The Mixed Meal Tolerance Test Versus the IV Glucagon Stimulation Test for the Assessment of Beta Cell Function in Type 1 Diabetes. Proceedings of the Australian Diabetes Society 2006; Abstract 301, p.125
  40. Barker JM, Babu S, Fernando M, Greenbaum C, Mahon J, Skyler JS, Eisenbarth GS, and the TrialNet study group. Low prevalence of DQA*0102 DQB*0602 subjects with Trialnet Initial Biochemical Autoantibody Screening. Diabetes 2006; 55:(Supplement): A251 (1061-P).
  41. Lachin JM, Friedenberg P, Greenbaum C, and Type 1 Diabetes TrialNet. The Mixed Meal Tolerance Test versus the IV Glucagon Stimulation Test for the Assessment of Beta Cell Function in Type 1 Diabetes. Diabetes 2006; 55:(Supplement): A537 (2325-PO).
  42. 2007

  43. Sosenko JM, Krischer JP, Palmer JP, Mahon J, Cowie C, Greenbaum CJ, Cuthbertson DD, Lachin J, Skyler JS, and the DPT-1 Study Group. A Risk Score for Type 1 Diabetes Derived from Participants in the Diabetes Prevention Trial-Type 1 (DPT-1). Diabetes 2007; 56:(Supplement 1): A-55 (Abstract 210-0)
  44. Herold KC, for the Type 1 Diabetes TrialNet Study Group, the TrialNet Study Group Mechanistic Assay Committee, and the TrialNet T-Cell Assay Group. Report of the TrialNet T-Cell Validation Study in Type 1 Diabetes. Diabetes 2007; 56:(Supplement 1): A-319 (Abstract 1299-P)
  45. Mari A, Ferrannini E, Skyler JS, and the DPT-1 Study Group. Mechanisms of Progression to Diabetes in Relatives of Type 1 Diabetic Patients. Diabetes 2007; 56:(Supplement 1): A-384 (Abstract 1499-P)
  46. Sosenko JM, Wherrett D, Rafkin-Mervis L, Palmer JP, Skyler JS, and the DPT-1 Study Group. Metabolic Characteristics of Converters to ICA Positivity in the Diabetes Prevention Trial-Type 1 (DPT-1). Diabetes 2007; 56: (Supplement 1): A-482 (Abstract 1907-P)
  47. Mahon J, Sosenko J, Lachin J, Krause-Steinrauf H, Rafkin-Mervis L, Eisenbarth G, Palmer J, Thompson C, Skyler J,for the Type 1 Diabetes TrialNet Study Group. The Prevalence of Glucose Tolerance Abnormalities According to Autoantibody Number in the Type 1 Diabetes TrialNet Natural History Study. Diabetes 2007; 56:(Supplement 1): A-486 (Abstract 1922-P)
  48. Chase HP, Asare S, Greenbaum C, Lachin J, Lescheck E, Krause-Steinrauf H, Rafkin-Mervis L, Clare-Salzler M, for the Type 1 Diabetes TrialNet NIP Study Group. Nutritional Intervention to Prevent (NIP) Type 1 Diabetes. Diabetes 2007; 56:(Supplement 1): A-689 (Abstract 2723-PO)
  49. Krischer JP for the Type 1 Diabetes TrialNet Oral Insulin Study Group. Oral Insulin For the Prevention Of Diabetes In Relatives At Risk For Type 1 Diabetes Mellitus (T1DM). Diabetes 2007; 56:(Supplement 1): A-699 (Abstract 2764-PO)
  50. Mahon J, Sosenko JM, Lachin J, Krause-Steinrauf H, Rafkin-Mervis L, Eisenbarth GS, Palmer JP, Thompson C, and The Type 1 Diabetes TrialNet Study Group. The Prevalence of Glucose Tolerance Abnormalities According to Autoantibody Number in the Type 1 Diabetes TrialNet Natural History Study. Acta Diabetologia 2007; 44:(Supplement 1): S 30.
  51. Herold K for the Mechanistic Outcomes Committee and the Type 1 Diabetes TrialNet Study Group. Report from TrialNet: Diagnostic Accuracy and Reproducibility of T-Cell Responses to Islet Antigens in Subjects with Recently Diagnosed Type 1 Diabetes. Acta Diabetologia 2007; 44:(Supplement 1): S 21.
  52. Sosenko JM, Rafkin-Mervis L, Mahon J, Lachin J, Krause-Steinrauf H, Krischer J, Cuthbertson D, Palmer JP, Skyler JS, and the DPT-1 and Type 1 Diabetes TrialNet Study Groups. Comparison Between Participants of the TrialNet Natural History Study and Participants of the Diabetes prevention Trial-Type 1. Acta Diabetologia 2007; 44:(Supplement 1): S 50.
  53. Sosenko JM, Palmer JP, Rafkin-Mervis L, Krischer J, Cuthbertson D, Matheson D, Skyler JS, and the DPT-1 Study Group. Glucose and C-Peptide Changes in the Peri-onset Period of Type 1 Diabetes in the Diabetes Prevention Trial – Type 1 (DPT-1). Acta Diabetologia 2007; 44:(Supplement 1): S 49-50.
  54. 2008

  55. Ferrannini E, Nofrate V, Skyler JS, Mari A, for the DPT-1 Study Group. Progression to diabetes in relatives of people with type 1 diabetes: predictors and mode of onset. Diabetes 2008; 57:(Supplement 1): A-45 (Abstract 150-OR).
  56. Sosenko JM, Rafkin-Mervis L, Mahon J, Lachin J, Krause-Steinrauf H, Krischer J, Cuthbertson D, Palmer JP, Thompson C, Skyler JS, and the Diabetes Prevention Trial-Type 1 Diabetes (DPT-1) and Type 1 Diabetes TrialNet Study Groups. Comparisons of OGTT Indices between Participants of the TrialNet Natural History Study and Participants of the Diabetes Prevention Trial-Type 1. Diabetes 2008; 57:(Supplement 1): A-264 (Abstract 914-P).
  57. Sosenko JM, Palmer JP, Rafkin-Mervis L, Krischer J, Cuthbertson D, Skyler JS, and the DPT-1 Study Group. The Loss of Post-Challenge C-Peptide Levels in the Peri-Onset Period of Type 1 Diabetes in the Diabetes Prevention Trial-Type 1 (DPT-1). Diabetes 2008; 57:(Supplement 1): A-502 (Abstract 1810).
  58. Sosenko JM, Palmer JP, Rafkin-Mervis L, Krischer J, Cuthbertson D, Matheson D, Skyler JS, and the DPT-1 Study Group. Incident Post-Challenge Dysglycemia as a Predictor of Type 1 Diabetes in the Diabetes Prevention Trial-Type 1 (DPT-1). Diabetes 2008; 57:(Supplement 1): A-66 (Abstract 228-OR).
  59. Triolo TM, Chase HP, Barker JM, and the DPT-1 Study Group. Subjects Diagnosed with Diabetes through the Diabetes Prevention Trial Type 1 (DPT-1) are Often Asymptomatic and Have Rare Ketosis at Onset. Diabetes 2008; 57:(Supplement 1): A-501-502 (Abstract 1807).
  60. 2009

  61. Sosenko J, Palmer J, Rafkin-Mervis L, Krischer J, Cuthbertson D, Greenbaum C, Skyler JS, The DPT-1 Study Group.The Timing of the Peak C-Peptide and Its Prediction of Type 1 Diabetes in the Diabetes Prevention Trial-Type 1 (DPT-1). Diabetes 2009; 58: (Supplement 1): Abstract 22-OR.
  62. Pescovitz MD, Torgerson TR, Ochs HD, Ocheltree E, Mcgee P, Krause-Steinrauf H, for the Type 1 Diabetes Trial Network (TrialNet). In Vivo Immune Responses in Type 1 Diabetes Following Treatment with Rituximab. Diabetes 2009; 58: (Supplement 1): Abstract 195-OR.
  63. Jeffrey J, Eisenbarth GS, Fain PR, Yu L, Miao D. Persistent but Not Transient Biochemical Islet Autoantibody Expression Is Increased in Prospectively Followed Monozygotic Versus Dizygotic Twins.Diabetes 2009; 58: (Supplement 1): Abstract 1141-P.
  64. Sosenko J, Palmer J, Rafkin-Mervis L, Krischer J, Cuthbertson D, Greenbaum C, Skyler JS, The DPT-1 Study Group.Trends of Earlier and Later C-Peptide Responses to Oral Glucose with Progression to Type 1 Diabetes in the Diabetes Prevention Trial-Type 1 (DPT-1). Diabetes 2009; 58: (Supplement 1): Abstract 1801-P.
  65. Vehik K, Haller MJ, Xu P, Schatz DA, Krischer J, DPT-1 Study Group. Seroconversion in the DPT-1 Study: evidence of triggering of autoimmune process at different ages. Diabetologia 2009; 52: (Supplement 1) S 119 (Abstract 277).
  66. 2010

  67. Paula McGee, Heidi Krause-Steinrauf, Mark Pescovitz, Kevan Herold, Jay Skyler, Carla Greenbaum, Lisa Spain, John Lachin for the Type 1 Diabetes TrialNet. Selection of A Clinical Response Criterion. Clin Trials 7(4):493, 2010.
  68. Sosenko J, Skyler J, Krischer J, Greenbaum C, Rafkin L, Mahon J, Cuthbertson D, Palmer J, and The Dpt-1 Study Group. Transient Diabetic Range Oral Glucose Tolerance Tests and Their
    Possible Relation to Insulin Resistance Prior to the Diagnosis of Type 1Diabetes in the Diabetes Prevention Trial−Type 1 (DPT−1). Diabetes 2010;59:(Suppl 1):A499 (Abstract 1906-P).
  69. Sosenko J, Skyler J, Palmer J., Krischer J, Cuthbertson D, Yu L, Schatz D, Orban T, Eisenbarth G, and The DPT-1 Study Group. Quantitative Changes in ICA512 and GAD65Autoantibodies with Progression to Type 1 Diabetes in the Diabetes Prevention Trial−Type1 (DPT−1). Diabetes 2010;59(Suppl 1):A19 (Abstract 0068-OR).
  70. Vehik K, Beam C, Haller M, Sosenko J, Schatz D, Mahon J, Krischer J, Skyler J, for the Type 1 Diabetes TrialNet Study Group. Development of Autoantibodies in the TrialNet Natural History Study (NHS). Diabetes 2010;59:(Suppl 1):A57 (Abstract 0213-OR).
  71. Chase P, Boulware D, Krischer J, Daniels M, Nathan B, Chritton S, Muller S, Clare-SalzlerM, and the TrialNet Nutritional Intervention to Prevent (NIP) Diabetes Study Group. Vitamin D and Inflammatory Cytokine Levels in Infants at High Genetic Risk for Type 1Diabetes. Diabetes 2010;59:(Suppl 1):A467 (Abstract 1785-P).
  72. Chase P, Boulware D, Krischer J, Rodriguez H, Donaldson D, Chritton S, Muller S, Clare- Salzler M, and the TrialNet Nutritional Intervention to Prevent (NIP) Diabetes Study Group. Inflammatory Cytokines in the Pre-Autoimmune Phase of Type 1 Diabetes. Diabetes2010;59:(Suppl 1): A502 (Abstract 1918-P).
  73. Ferrannini E, Mari A, Nofrate V, Krischer J, Sosenko J, Skyler J, for the DPT-1 Study Group. Prediction of Diabetes in Relatives of People with Type 1 Diabetes: Role of Clinical Testing. Diabetes 2010;59:(Suppl 1):A63 (Abstract 0236-OR).
  74. Brooks-Worrell B, Beam C, Reichow J, Palmer J and the Type 1 Diabetes TrialNet Study Group. Rituximab Transiently Affects Islet Specific T Cell Responses in Type 1 Diabetes Patients. Clinical Immunology 2010;135:S97 (FOCIS Abstract F.69).
  75. Pescovitz M, McGee P, Krause-Steinrauf H, Canniff J, Weinberg A, Skyler J and Type 1 Diabetes TrialNet Study Group. Human In Vivo De Novo and Recall Antibody Responses after Rituximab Treatment for Type 1 Diabetes. Clinical Immunology 2010;135:S32 (FOCIS Abstract OR.77).
  76. Buckingham B, Wilson D, Weinzimer S, Sherr J, Block J, Slover R, Chase P and the Type1 Diabetes TrialNet Study Group. Use of a Hybrid Closed-Loop (HCL) to Restore Metabolic Control at the Onset of Diabetes. Diabetes Technology Meeting, Poster Presentation, Bethesda, MD, November 11-13, 2010. J Diabetes Science & Technology 2010;4(2), A17.
  77. 2011

  78. Buckingham B, Wilson DM, Slover R, Chase HP, Weinzimer S, Sherr J, Block J, Xing D, Ruedy K for the ICAN (Intenstive Control at oNset) Study Group. Effect of a Hybrid Closed-Loop (HCL) on Restoring Metabolic Control at the Onset of Diabetes. ATTD (Advanced Technologies and Treatments for Diabetes. London, UK February 16-19, 2011. Oral Presentation. Diabetes Technology & Therapeutics 2011;13(2):176-177 (Abstract O-09).
  79. Vehik K, Beam CA, Boulware D, Schatz DA, Krischer JP and the TrialNet Study Group. Autoantibody Reversion in the TrialNet Natural History Study. American Diabetes Association. San Diego, CA, June 24-28, 2011. Guided Audio Poster Tour and General Poster Session. Diabetes 2011:60 (Suppl 1):A353 (Abstract 1286-P).
  80. Buckingham B, Wilson DM, Slover R, Chase HP, Weinzimer S, Sherr J, Block J, Xing D, Ruedy K for the DirecNet and TrialNet Study Groups. Effect of a Hybrid Closed-Loop (HCL) on Restoring Metabolic Control at the Onset of Diabetes. American Diabetes Association. San Diego, CA, June 24-28, 2011. Guided Audio Poster Tour and General Poster Session. Diabetes 2011:60 (Suppl 1):A237 (Abstract 873-P).
  81. Buckingham B, Buckingham J, Uttarwar A, Slover R and Messer L. The Accuracy of the GlucoScout Blood Glucose Monitor in Inpatient Monitoring of Patients with Type 1Diabetes. American Diabetes Association. San Diego, CA, June 24-28, 2011. Guided Audio Poster Tour and General Poster Session. Diabetes 2011:60 (Suppl 1): A236 (Abstract 869-P).
  82. Wherrett DK for Type 1 Diabetes Trialnet Study Group. Rapid Enrollment to GAD65-Alum Trial in Recent-Onset Type 1 Diabetes Including Subjects as Young as Age 3. American Diabetes Association. San Diego, CA, June 24-28, 2011. Diabetes 2011:60 (Suppl 1):A670 (Abstract 2542-PO).
  83. Sosenko J, Skyler J, Mahon J, Krischer J, Greenbaum C, Rafkin L, Beam C, Boulware D, Matheson D , Cuthbertson D, Eisenbarth G, Palmer J, DPT-1/TrialNet Study Groups. The Use of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) for Identifying Normoglycemic Individuals at High Risk for Type 1 Diabetes. American Diabetes Association. San Diego, CA, June 24-28, 2011. Oral Presentation. Diabetes 2011:60 (Suppl 1):A43 (Abstract 158-OR).
  84. Sosenko J, Skyler J, Mahon J, Krischer J, Greenbaum C, Rafkin L, Matheson D, Cowie C, Beam C, Boulware D, Cuthbertson D, Palmer J, Diabetes Prevention Trial-Type 1/TrialNet Study Groups. The OGTT Index as an Indicator of the Pre-Diabetic State of Type 1Diabetes in Children. American Diabetes Association. San Diego, CA, June 24-28, 2011. Guided Audio Poster Tour and General Poster Session. Diabetes 2011:60 (Suppl 1):A334 (Abstract 1214-P).
  85. Bennett Johnson S, Rafkin L, Boulware D, Pescovitz M and the Type 1 Diabetes TrialNet Study Group. Participant and Parent Experiences in a Rituximab Trial to Preserve Beta Cell Function. American Diabetes Association. San Diego, CA, June 24-28, 2011. Poster Presentation. Diabetes 2011:60 (Suppl 1):A230 (Abstract 848-P).
  86. McGee P, Krause-Steinrauf H, Greenbaum C, Pescovitz M, Herold K, Spain L, Skyler J, Lachin JM for Type 1 Diabetes TrialNet. Classification of a Clinical Responder for Evaluation of Treatment Efficacy in Trials of New-Onset Type 1 Diabetes. American Diabetes Association. San Diego, CA, June 24-28, 2011.Jeffrey J, Yu L, Steck A, Hayes B, Eisenbarth GS, Fain PK, Type 1 Diabetes TralNet Study Group. Initially Discordant TrialNet Twins. American Diabetes Association. San Diego, CA, June 24-28, 2011. Presidents Poster Reception and Session. Diabetes 2011:60 (Suppl 1):A121 (Abstract 437-PP).
  87. Jeffrey J, Yu L, Steck A, Hayes B, Eisenbarth GS, Fain PK, Type 1 Diabetes TrialNet Study Group. Initially Discordant TrialNet Twins. American Diabetes Association. San Diego, CA, June 24-28, 2011. Poster Presentation. Diabetes 2011:60 (Suppl 1):A383 (Abstract 1394-P).
  88. Yu L, Mahon J, Boulware D, Hutton J, Wenzlau J, Beam C, Eisenbarth G, Bingley P, Krischer J, Sosenko J, TrialNet Study Group. Zinc Transporter-8 Autoantibodies (ZnT8A) Increase Type 1 Diabetes (T1D) Risk in Single Autoantibody Positive Relatives. American Diabetes Association. San Diego, CA, June 24-28, 2011. Oral Presentation. Diabetes2011:60 (Suppl 1):A71 (Abstract 260-OR).
  89. Vehik K, Schatz D, Boulware D, Cuthbertson D, Beam C, Vavrinec J, Rodriguez H, Legault L, Krischer J on behalf of the DPT-1, TEDDY, TRIGR and TrialNet Study Groups. Hemoglobin A1c as an Indicator of Type 1 Diabetes in Pediatric and Adolescent Youth. 47th EASD Annual Meeting, Lisbon, Portugal, Sept 12-16, 2011. Accepted for Oral Presentation. Diabetologia2011;54:(Suppl 1) (Abstract 80OR, S40).
  90. 2012

  91. Ambrosino JM, Weinzimer SA, Steffen AT, Ruedy K for the DirectNet and TrialNet Study Groups. Short-Term Psychosocial Impact of Sensor-Augmented Pump Therapy Within Three Months of Diagnosis of Type 1 Diabetes. Publication only. Diabetes 2012;61 (Suppl 1):A586 (Abstract 2327-PO).
  92. Buckingham B, Slover R, Weinzimer S, DiMeglio LA, Bremer A, Cantwell M, Xing D, Ruedy K for the DirecNet and TrialNet Study Groups. Effect of a Hybrid Closed-Loop (HCL) on Restoring Metabolic Control at the Onset of Diabetes. Poster Presentation. Diabetes 2012;61 (Suppl 1):A226 (Abstract 891-P).

  93. Beam CA, Gitelman S, Herold K, Krischer J. Misclassification of Subjects with Preserved C-peptide as "Clinical Non-Responders" Occurs Frequently and May Attenuate Biologic Significance. Publication Only. Diabetes 2012;61 (Suppl 1):A597 (2368-PO).
  94. Pugliese A, Boulware D, Babu S, Steck A, Beam C, Becker D, Eisenbarth GS, Greenbaum C and the Type 1 Diabetes TrialNet Study Group. The HLA-DR2, DQB1*0602 Haplotype is Associated with Lack of Disease Progression and Lower Autoantibody Prevalence in the TrialNet Natural History Study. Oral Presentation. Diabetes 2012;61 (Suppl 1):A94 (Abstract 360-OR).
  95. Sosenko J, Skyler J, Eisenbarth G, Krischer J, Yu L, Mahon J, Beam C, Boulware D, Rafkin L, Schatz D, Palmer J, the Type 1 Diabetes TrialNet Study Group. The Prediction of Type 1 Diabetes by Multiple Autoantibody Levels and Their Incorporation into an Autoantibody Risk Score in the TrialNet Natural History Study. Oral Presentation. Diabetes 2012;61 (Suppl 1):A54 (Abstract 202-OR).
  96. Sosenko J, Skyler J, Krischer J, Herold K, Greenbaum C, Rafkin L, Cuthbertson D, Palmer J, The Diabetes Prevention Trial-Type 1, the Type 1 Diabetes TrialNet Study Group. Characteristic Insulin Secretion Patterns Persist at the Diagnosis of Type 1 Diabetes in the Diabetes Prevention Trial-Type 1 (DPT-1). Poster Presentation. Diabetes 2012;61 (Suppl 1):A324 (Abstract 1256-P).
  97. Ismail HM, White KS, Krischer JP, Chase HP, Cuthbertson D, Palmer JP, DPT-1 Study Group. A First Test Effect in Intravenous Glucose Tolerance Tests Seen in Relatives of Subjects with Type 1 Diabetes. Endocrine Society, 94th Annual Meeting, Poster Presentation. Endocrine Reviews 2012;33:SUN 212.

  98. 2013

  99. Buckingham, B, Chase P, Weinzimer S, Russell W, DiMeglio L, Wilson D, Tamborlane W, Sherr J, Slover R, Bremer A, Ruedy K, Kollman C, Cheng P, Beck R and the Type 1 Diabetes TrialNet Study Group. Does Intensive Metabolic Control at the Onset of Diabetes Followed by One Year of Sensor Augmented Pump Therapy Improve C-peptide Levels One Year Post Diagnosis? Advanced Technology and Treatments for Diabetes (ATTD). Oral Presentation. Diabetes Technol Ther 2013;15(S1):A-137 (L-01).

back to top of page